Company intelligence / Profile preview
Avirmax Biopharma
Hayward, California, USAavirmax.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ABI‑110 has completed enrollment of the first cohort in a Phase I/IIa trial for wet AMD/PCV with no serious adverse events or dose-limiting toxicities reported so far. Preclinical data show improved macular tropism and durable expression. ABI‑201 has entered IND-enabling studies targeting dry AMD with promising animal data.[4][7]
- Therapeutic areas
- Ophthalmology
- Modalities
- AAV-based gene therapy (recombinant adeno-associated virus vectors)Gene transfer technologiesAntibody
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Avirmax Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avirmax Biopharma.